Member Info for Toffers

Looks like loads of people sold out yesterday on the rise yesterday and are waiting to try and get back in lower today and in the coming weeks. Stinks of total manipulation by the Mms et al. The weird trades and then virtually no rise today, and the knock back last night and this morning showing false high information when we reached 3.60p yesterday and yet they knocked it down to 3.225p overnight and then lower again straight after this mornings rns. How can this site keep altering the close price? and the high price?

Number of employees: 11-50

same source

Health Care

Medical

Headquarters Regions

European Union (EU), Europe, Middle East, and Africa (EMEA)

Founded Date

2010

Operating Status

Active

Company Type

For Profit

Spun out of GlaxoSmithKline Pharmaceuticals (GSK) in 2010, Transpharmation was created to be a CRO with a difference; cross therapeutic area expertise in translational pharmacology from bench to bedside.

With headquarters based in central London, England and laboratories just north of the Captial, Transpharmation is rapidly growing and buckingthe trend in the languishing CRO market since the financial crisis in 2007/2008.

Transpharmation is led by a team with years of proven hands-on drug discovery and business expertise. This has allowed us to build client and science-focused relationships, across their extensive network in the pharmaceutical and biotechnology sectors.

Their mission is simple; they wish to be known as the market leader in the provision of innovation and science-led translational biology. They believe, they have made significant steps to achieving this goal and invite you to explore their website to further understand how their strategy can enhance your Drug Discovery programmes.

Products and Services

Powered by AI

Product Name

Product Description

Translational Drug Discovery Services

Offers preclinical research services with animal models to provide data for drug development, focusing on age-related diseases like Alzheimer's and osteoarthritic pain.

Molecular Biomarkers & Histology

Provides biomarker identification and histological analysis to predict drug efficacy and improve clinical translation, using advanced imaging technologies.

Neuropathic Pain Models

Develops models for neuropathic pain research, including chronic constriction injury, diabetic-induced neuropathy, and chemotherapy-induced neuropathy.

Operant Platform

A rodent testing platform for evaluating new chemical entities against behavioral symptoms such as motivation, impulsivity, and anxiety.

Parkinson's Disease Models

Utilizes the rotenone rat model to study Parkinsonism, assessing behavioral, biochemical, and anatomical endpoints.

PK/PD Studies

Conducts pharmacokinetic and pharmacodynamic assays to support lead optimization in drug discovery, offering various dosing routes and species.

source: crunchbase.com

Hi Hightower, companies house

Next accounts made up to 31 January 2025 due by 31 July 2025

Last accounts made up to 31 December 2023

Confirmation statement

Next statement date 18 July 2025 due by 1 August 2025

Last statement dated 18 July 2024

UNBELIEVABLE JEFF! The sp is now lower than yesterdays close and yesterday there was no COMMERCIAL AGREEMENT!

COMMERCIAL AGREEMENT and the blighters are really messing around with the sp. Looks like we're in for late reported buy trades. Someone really wants this held down for that purpose. Someone has been block buying for weeks, definitely for a purpose! imo.

As the sp is being messed about with!

Looking to get in are we for a low entry? no chance! Onwards and upwards. I think LTHs know where this is going imo.

Thanks for the TA analysis TWK, onwards and upwards! 🤞

Let's see what happens with Plant's broker prediction of sp around 65p within 12-18 months from last December!

EXCITING!

LET THE SQUEEEEEEEEEZE BEGIN :)

Hopefully he's taken his Anxiety elsewhere TWK! :)

Let's all scream, COMMERCIAL AGREEMENT :)

Well done Cykel, keep them coming :)

TWK a scam artist will always take your money from you!!!! :)

Look below, we were 3.225p before the rns and then they've changed the sp straight after the rns to 3.09p! JOKERS! Onwards and upwards. TWK how are the bollie bands looking now?

Https://www.transpharmation.com/

Https://find-and-update.company-information.service.gov.uk/company/07348226/officers

Cykel AI Secures Enterprise-Level Commercial Agreement with Transpharmation, Generating New Revenue Stream in Pharmaceutical Sector

Cykel AI PLC (LSE: CYK) is pleased to announce the signing of a commercial agreement with Transpharmation Ltd., a global leader in neuroscience, pain and metabolic disease preclinical contract research. Transpharmation will deploy Lucy, Cykel's AI recruitment agent, across their UK and North American operations, opening a new revenue stream for Cykel in the pharmaceutical research sector. The agreement includes an initial 12-month term with renewal options for Lucy's Enterprise plan.

Coming after Transpharmation's recent acquisition of biomarker technology provider Saretius, this commercial deployment supports Transpharmation's market leadership in pharmaceutical research services. With over 150 employees and sites spanning two continents, Transpharmation has chosen an enterprise subscription to support the expansion of their team and operations.

Dr Mark Duxon PhD, Chief Executive Officer at Transpharmation Ltd, said: "As a company dedicated to advancing therapeutic medicine through cutting-edge research, we recognise the importance of securing the brightest scientific minds. Our investment in Cykel's AI recruitment technology reflects our commitment to innovation not just in our research methodologies, but in how we acquire talent efficiently and cost-effectively. After evaluating multiple options, we selected Lucy for her autonomous recruitment capabilities and alignment with our mission to build world-class research teams while optimising operational expenses."

Transpharmation has subscribed to Cykel's Enterprise plan, which carries the highest subscription value in Cykel's tiered pricing model. This premium subscription provides access to Lucy's full suite of functionalities, including:

● AI-powered search across 300 million professional profiles

● Automated multi-channel outreach

● Integration with ATS systems

● Advanced AI screening and talent matching

● Customisation options tailored to Transpharmation's requirements

● Unlimited workspace capacity to support their global operations

With the global pharmaceutical market valued at £1.25 trillion in 2023, this agreement underscores Lucy's commercial value proposition in this high-growth segment and marks a step forward in Cykel's ability to monetise its technology in regulated, knowledge-intensive industries.

Ewan Collinge, CEO & Founder of Cykel AI, commented: "Securing Transpharmation as a customer endorses our commercial strategy and product-market fit in knowledge-intensive sectors. This agreement not only generates revenue but establishes a foundation for expanded commercial opportunities as Transpharmation explores additional digital workers in their operations. The enterprise-level contract reflects the scalability of our pricing model and our ability to convert market-leading companies into customers."

It's a very big bang itshenderz :) oh joy! and hopefully many more to come - no wonder someone appears to be accummulating Stateside!

Is that 12.5 million shares in larger trades bought this afternoon? someone Stateside is filling their boots! imo.